Patents by Inventor Peter Snyder
Peter Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131062Abstract: The spray dried plasma by the nature of its characteristics and the process by which it is made allows for a dried plasma with reduced pathogens. It has at least three aspects of pathogen reduction that results in a plasma product with reduced or no pathogens. The first aspect relates to a spray drying disposable and machine that eliminates or minimizes the introduction of pathogens into the spray drying process and is referred to as the anti-contamination process. The second aspect of pathogen reduction relates to the spray drying process and parameters that reduces pathogens that may be present in the donor plasma, and/or inhibit pathogen growth and/or pathogen proliferation introduced by the donor plasma. The third aspect results in reduced pathogens occurring during storage of the dried plasma wherein the manufacturing and storage conditions are such that pathogens are reduced, and/or pathogen growth and/or pathogen proliferation are inhibited.Type: ApplicationFiled: September 14, 2023Publication date: April 25, 2024Applicant: Velico Medical, Inc.Inventors: Mark A. Popovsky, Lisa A. Buckley, Jihae Sohn, Evan P. Ordway, Qiyong Peter Liu, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Clair Strohl, Russell J Barron
-
Publication number: 20240131063Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the mean size of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment.Type: ApplicationFiled: September 14, 2023Publication date: April 25, 2024Applicant: Velico Medical, Inc.Inventors: Jihae Sohn, Lisa A. Buckley, Mark A. Popovsky, Qiyong Peter Liu, Herman E. Snyder, Evan P. Ordway, William J. Merritt, Robert R. Andrews, Clair Strohl
-
Publication number: 20240123368Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: ApplicationFiled: January 17, 2023Publication date: April 18, 2024Applicant: Velico Medical, Inc.Inventors: Robert R. Andrews, Herman E. Snyder, William J. Merritt, Evan P. Ordway, Clair Strohl, Qiyong Peter Liu, Jihae Sohn
-
Patent number: 11960834Abstract: An attention application, such as a web browser, includes a pipeline optimized for faster, more secure, and more private, viewing of hypermedia documents using a reader mode. The reader mode is “always on” in the sense that a classifier runs on every web page and every compatible page is rendered in the reader mode and not rendered in full, referred to as the bloat page. Significant time savings are gained by avoiding fetching and rendering the bloat page at all because the bloat page devours network bandwidth and computing resources. Avoiding loading the bloat page also avoids exposing the user to what are often abusive privacy infringements and security vulnerabilities from running executable code in the browser, while providing an uncluttered viewing experience of content that is actually of interest to the user.Type: GrantFiled: September 30, 2019Date of Patent: April 16, 2024Assignee: Brave Software, Inc.Inventors: Benjamin Livshits, Peter Snyder, Andrius Aucinas
-
Publication number: 20240109000Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: ApplicationFiled: September 15, 2022Publication date: April 4, 2024Applicant: Velico Medical, Inc.Inventors: Qiyong Peter Liu, Herman E. Snyder, Kyle D. Erickson, Evan P. Ordway, William J. Merritt, Richard Meehan, Robert R. Andrews, Clair Strohl, Jihae Sohn
-
Publication number: 20240091666Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: ApplicationFiled: January 17, 2023Publication date: March 21, 2024Applicant: Velico Medical, Inc.Inventors: Richard Meehan, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Evan P. Ordway, Clair Strohl, Qiyong Peter Liu, Jihae Sohn
-
Patent number: 11717481Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: GrantFiled: December 3, 2021Date of Patent: August 8, 2023Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Publication number: 20220211626Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: December 3, 2021Publication date: July 7, 2022Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Patent number: 11253478Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: GrantFiled: May 4, 2018Date of Patent: February 22, 2022Assignee: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Publication number: 20210097134Abstract: An attention application, such as a web browser, includes a pipeline optimized for faster, more secure, and more private, viewing of hypermedia documents using a reader mode. The reader mode is “always on” in the sense that a classifier runs on every web page and every compatible page is rendered in the reader mode and not rendered in full, referred to as the bloat page. Significant time savings are gained by avoiding fetching and rendering the bloat page at all because the bloat page devours network bandwidth and computing resources. Avoiding loading the bloat page also avoids exposing the user to what are often abusive privacy infringements and security vulnerabilities from running executable code in the browser, while providing an uncluttered viewing experience of content that is actually of interest to the user.Type: ApplicationFiled: September 30, 2019Publication date: April 1, 2021Applicant: Brave Software, Inc.Inventors: Benjamin Livshits, Peter Snyder, Andrius Aucinas
-
Publication number: 20180250229Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: May 4, 2018Publication date: September 6, 2018Applicant: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Publication number: 20180162849Abstract: A crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is provided which is useful in the treatment of infections caused by Picornaviridae such as human rhinovirus (HRV), and in particular the crystal form is an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole. In addition, a method of manufacturing the free base crystalline form is also provided, including a step of micronizing the compound particles, optionally using a wetting agent, as well as pharmaceutical compositions incorporating the free base crystalline form such as tablets or suspensions, and methods of therapeutic treatments using this form and pharmaceutical compositions thereof.Type: ApplicationFiled: September 22, 2017Publication date: June 14, 2018Inventors: Edward LEE, David MCALLISTER, Andrew TRIGWELL, Robert Vincent TUOHY, III, Peter SNYDER, JR., Christa Leisa FRASSETTO
-
Patent number: 9974746Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: GrantFiled: April 15, 2016Date of Patent: May 22, 2018Assignee: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Patent number: 9974748Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: GrantFiled: April 15, 2016Date of Patent: May 22, 2018Assignee: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Patent number: 9974747Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: GrantFiled: April 15, 2016Date of Patent: May 22, 2018Assignee: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Patent number: 9802926Abstract: A crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is provided which is useful in the treatment of infections caused by Picornaviridae such as human rhinovirus (HRV), and in particular the crystal form is an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole. In addition, a method of manufacturing the free base crystalline form is also provided, including a step of micronizing the compound particles, optionally using a wetting agent, as well as pharmaceutical compositions incorporating the free base crystalline form such as tablets or suspensions, and methods of therapeutic treatments using this form and pharmaceutical compositions thereof.Type: GrantFiled: June 19, 2015Date of Patent: October 31, 2017Assignee: AVIRAGEN THERAPEUTICS, INC.Inventors: Edward Lee, David McAllister, Andrew Trigwell, Robert Vincent Tuohy, III, Peter Snyder, Jr., Christa Leisa Frassetto
-
Patent number: 9693507Abstract: The hedger trimming carriage and apparatus is a frame that is designed to be mounted on a vehicle. The frame of the hedger trimming carriage and apparatus is designed to carry during operation a hedger that is used to trim bushes and shrubbery while the vehicle is in motion. The hedger trimming carriage and apparatus comprises a mounting frame, a first hedger apparatus, and as second hedger apparatus.Type: GrantFiled: October 27, 2015Date of Patent: July 4, 2017Inventor: Peter Snyder
-
Publication number: 20160228555Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: April 15, 2016Publication date: August 11, 2016Applicant: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Publication number: 20160228372Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: April 15, 2016Publication date: August 11, 2016Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
-
Publication number: 20160228554Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.Type: ApplicationFiled: April 15, 2016Publication date: August 11, 2016Applicant: Alkermes Pharma Ireland LimitedInventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer